Clinical trials: Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma
Rigosertib for RDEB-SCC
Epidermolysis bullosa (EB) is a heritable skin disease characterized by marked fragility of epithelialized tissue with blistering in skin and mucous membranes following the slightest mechanical trauma.
- Trial name
- NCT03786237
- Testing
- Rigosertib Oral Capsules / Rigosertib Intravenous
- Where
- Austria
- Volunteers
- 2 people
- Sponsor
- Prof. Johann Bauer
Dystrophic Epidermolysis Bullosa
Short Term Observational Study in DEB Patients
The purpose of this study is to better understand disease extent and to identify appropriate methodologies to evaluate (dystrophic epidermolysis bullosa) DEB in a quantitative and qualitative manner.
- Trial name
- NCT02178969
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 29 people
- Sponsor
- Shire
Epidermolysis Bullosa
Establishment of the National Epidermolysis Bullosa Registry
OBJECTIVES: I. Develop a large roster of well-characterized patients with various forms of inherited and acquired epidermolysis bullosa (EB). II.
- Trial name
- NCT00004761
- Sponsor
- National Center for Research Resources (NCRR)
Recessive Dystrophic Epidermolysis Bullosa
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
A sub-set of patients who participated in PTR-01-002 will be enrolled in an open-label study, if they meet the study eligibility criteria.
- Trial name
- NCT05143190
- Testing
- PTR-01
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Phoenix Tissue Repair, Inc.
Epidermolysis Bullosa Simplex
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
This study evaluates the clinical effect of foot injection of the bacteria protein Botulinum toxin A on plantar pain in patients with EBS (epidermolysis bullosa simplex) or PC (pachyonychia congenita).
- Trial name
- NCT00936533
- Testing
- Dysport® (Botulinumtoxin A (Btx A))
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University
Epidermolysis Bullosa
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
This is an open-label, single institution, phase II study in patients with epidermolysis bullosa (EB). The underlying hypothesis is that the infusion of bone marrow or umbilical cord blood from a healthy unaffected donor will…
- Trial name
- NCT01033552
- Testing
- Cyclophosphamide, Fludarabine, Anti-thymocyte globulin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recessive Dystrophic Epidermolysis Bullosa
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults.
- Trial name
- RDEB (NCT01874769)
- Testing
- Blood collection, Skin biopsies
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Epidermolysis Bullosa Dystrophica
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their…
- Trial name
- NCT01019148
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Dystrophic Epidermolysis Bullosa
A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa
This is a pilot study designed to see if HP802-247, an investigational treatment with living human skin cells, helps to heal blisters or wounds in subjects with Dystrophic Epidermolysis Bullosa (DEB).
- Trial name
- NCT01528306
- Testing
- HP802-247
- Sponsor
- Healthpoint
Dystrophic Epidermolysis Bullosa, Wound Heal
Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a hereditary disease of skin tissues that causes painful bleeding blisters in the skin and mucous membrane. The prevalence of this disease is 1 in 50,000.
- Trial name
- NCT07230223
- Testing
- Ev.FV 1.0 x 1011 par/ml
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Isfahan University of Medical Sciences
Epidermolysis Bullosa
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB.
- Trial name
- RDEB (NCT00881556)
- Testing
- Palifermin, Fludarabine, Busulfan
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a group of inherited disorders characterized by fragility of the skin and mucous membranes within the basement membrane zone.
- Trial name
- MATHBULL (NCT06007235)
- Testing
- CACIPLIQ20
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Recessive Dystrophic Epidermolysis Bullosa
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Protocol PTR-01-001 is a Phase 1/2 study of PTR-01. The study is divided into an up to 4-week Screening Period, a 10-week Treatment Period and an 8-week Follow-up Period.
- Trial name
- PTR-01-001 (NCT03752905)
- Testing
- PTR-01, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Phoenix Tissue Repair, Inc.
Junctional Epidermolysis Bullosa
Optimizing IV Gentamicin in JEB
Herlitz junctional epidermolysis bullosa (H-JEB), an incurable and fatal inherited skin disease, is caused by loss-of-function mutations in LAMA3, LAMB3 and LAMC2.
- Trial name
- NCT04140786
- Testing
- Gentamicin Sulfate, Injectable
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Long-Term Follow-up Protocol
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc.
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Trial name
- NCT04917887
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Krystal Biotech, Inc.
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB.
- Conditions
- Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Trial name
- STEP (NCT06594393)
- Testing
- TCP-25 gel
- Where
- 13 sites in United States, France and 5 more
- Volunteers
- 32 people
- Sponsor
- Xinnate AB
Epidermolysis Bullosa
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or…
- Trial name
- NCT02582775
- Testing
- Thymoglobulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Inherited Epidermolysis Bullosa
A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients
Inherited epidermolysis bullosa (EB) is a genetic skin disorder characterized by skin fragility and recurrent blister formation.
- Trial name
- NCT03468322
- Testing
- AC-203, Vehicle
- Where
- 2 sites in Taiwan
- Volunteers
- 9 people
- Sponsor
- TWi Biotechnology, Inc.
Epidermolysis Bullosa, Epidermolysis Bullosa Simplex
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101…
- Trial name
- NCT03389308
- Testing
- diacerein 1% ointment
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Castle Creek Pharmaceuticals, LLC
Epidermolysis Bullosa
Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
This is a single-center study to investigate the effects of a topical cream on patients 12 years of age and older that have been diagnosed with epidermolysis bullosa.
- Trial name
- NCT02793960
- Testing
- topical BPM31510 3.0% Cream
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shasa Hu